|
CN108530364A
|
|
A kind of crystal form of 3- (4- methyl-1 H-imidazole-1-groups) -5- 5-trifluoromethylaniline mono-hydrochloric salts and its application
|
|
CN107641124A
|
|
A kind of pemetrexed diacid novel crystal forms and preparation method thereof
|
|
CN105837634A
|
|
Tedizolid phosphate crystal and preparation method thereof
|
|
CN106565716A
|
|
Idelalisib crystal form A and preparation method thereof
|
|
CN105237606A
|
|
Intermediate used for synthesis of desogestrel, and preparation method and application thereof
|
|
CN105237605A
|
|
Intermediate for synthesizing gestodene, preparation method therefor and application thereof
|
|
CN104926828A
|
|
Method for preparing d-biotin from dibenzyl biotin
|
|
CN104926900A
|
|
Method for preparing Capecitabine intermediate represented by formula I
|
|
CN104926806A
|
|
Synthetic method of lamivudine intermediate
|
|
CN104447684A
|
|
Pomalidomide crystal form and preparation method thereof
|
|
CN104341387A
|
|
Method for preparing N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidinamine
|
|
CN104163846A
|
|
Method for preparing drospirenone
|
|
CN104030936A
|
|
Preparation method of 3-carbamoylmethyl-5-methylcaproic acid
|
|
CN104031024A
|
|
Preparation method of lenalidomide or its acid salt
|
|
CN103896833A
|
|
Sorafenib tosylate solvate polymorphs and manufacturing method and application thereof
|
|
CN103893137A
|
|
Method for preparing prasugrel tablet
|
|
CN103896889A
|
|
Lapatinib intermediate as well as preparation method and application thereof
|
